{"id":"placebo-of-aprepitant","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4303169","moleculeType":"Small molecule","molecularWeight":"534.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this formulation is designed to be inert and pharmacologically inactive, serving as a control comparator in the phase 3 trial of aprepitant. Placebos are used to establish the true efficacy and safety profile of the active drug by accounting for natural disease progression and psychological effects.","oneSentence":"This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:00.201Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in aprepitant phase 3 clinical trial (likely chemotherapy-induced nausea and vomiting prevention)"}]},"trialDetails":[{"nctId":"NCT02811055","phase":"PHASE2","title":"Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2017-07-13","conditions":"Type 2 Diabetes, Hypertension","enrollment":5},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT07248280","phase":"PHASE3","title":"Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2026-02-27","conditions":"Nausea and Vomiting, Postoperative, Prevention","enrollment":260},{"nctId":"NCT04470622","phase":"PHASE2","title":"Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)","status":"TERMINATED","sponsor":"Heron Therapeutics","startDate":"2020-07-20","conditions":"COVID-19","enrollment":27},{"nctId":"NCT07371728","phase":"PHASE4","title":"Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery","status":"NOT_YET_RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2026-06-01","conditions":"Otologic Disease","enrollment":100},{"nctId":"NCT06007586","phase":"PHASE3","title":"Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients","status":"COMPLETED","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2024-05-31","conditions":"Gynecological Tumor, Ovarian Cancer, Cervical Cancer","enrollment":143},{"nctId":"NCT03808805","phase":"PHASE3","title":"Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2019-04-16","conditions":"Myeloproliferative Disorder, Aquagenic Pruritus","enrollment":63},{"nctId":"NCT06462287","phase":"PHASE2","title":"EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-03-05","conditions":"Apnea, Obstructive","enrollment":24},{"nctId":"NCT06932107","phase":"PHASE3","title":"Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting","status":"COMPLETED","sponsor":"Qilu Pharmaceutical (Hainan) Co., Ltd.","startDate":"2024-02-02","conditions":"Postoperative Nausea and Vomiting","enrollment":518},{"nctId":"NCT03578081","phase":"PHASE3","title":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-11-20","conditions":"Malignant Neoplasm","enrollment":690},{"nctId":"NCT05773950","phase":"NA","title":"Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention","status":"ENROLLING_BY_INVITATION","sponsor":"Samsung Medical Center","startDate":"2023-08-18","conditions":"Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures, Laparoscopy","enrollment":144},{"nctId":"NCT06357234","phase":"PHASE2","title":"Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery","status":"RECRUITING","sponsor":"IWK Health Centre","startDate":"2025-03-17","conditions":"Spinal Fusion, Nausea and Vomiting, Postoperative, Anesthesia","enrollment":100},{"nctId":"NCT01963793","phase":"PHASE2","title":"Topical Aprepitant in Prurigo Patients","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-10","conditions":"Pruritus","enrollment":20},{"nctId":"NCT05189756","phase":"PHASE4","title":"Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.","status":"TERMINATED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2022-03-17","conditions":"Postoperative Nausea and Vomiting, Bariatric Surgery","enrollment":71},{"nctId":"NCT02116530","phase":"PHASE3","title":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-08-20","conditions":"Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":401},{"nctId":"NCT00719173","phase":"PHASE1","title":"Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2005-08","conditions":"Breast Cancer, Nausea and Vomiting","enrollment":19},{"nctId":"NCT06593782","phase":"PHASE2","title":"Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2024-09-16","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":180},{"nctId":"NCT06543966","phase":"PHASE3","title":"Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting","status":"NOT_YET_RECRUITING","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2024-10-28","conditions":"Post-operative Nausea and Vomiting (PONV)","enrollment":486},{"nctId":"NCT01020903","phase":"NA","title":"Aprepitant for Post-operative Nausea","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2009-11","conditions":"Postoperative Nausea","enrollment":200},{"nctId":"NCT05772676","phase":"PHASE4","title":"The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting","status":"UNKNOWN","sponsor":"Hospital General Tlahuac","startDate":"2022-12-01","conditions":"Obesity, Nausea and Vomiting, Postoperative","enrollment":400},{"nctId":"NCT03674294","phase":"PHASE3","title":"Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08-04","conditions":"Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting","enrollment":248},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":106},{"nctId":"NCT01527994","phase":"PHASE1","title":"Aprepitant Effects in Intravenous Heroin Dependence","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2012-01","conditions":"Opioid Dependence","enrollment":64},{"nctId":"NCT02646020","phase":"PHASE2","title":"Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-12","conditions":"Non-small Cell Lung Cancer","enrollment":138},{"nctId":"NCT01661335","phase":"PHASE3","title":"Efficacy of Aprepitant (Emend®) in Children","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2012-06-01","conditions":"Nausea, Vomiting, Childhood Cancer","enrollment":19},{"nctId":"NCT01176591","phase":"PHASE2","title":"HBPL Study of the Impact of the NK1 Antagonist Aprepitant","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-09","conditions":"Cocaine Dependence, Alcohol Dependence","enrollment":13},{"nctId":"NCT02161991","phase":"PHASE3","title":"Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers","status":"COMPLETED","sponsor":"Hunan Province Tumor Hospital","startDate":"2014-02-01","conditions":"Carcinoma, Non-small Cell Lung","enrollment":244},{"nctId":"NCT02861859","phase":"PHASE3","title":"Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-12","conditions":"Breast Cancer","enrollment":221},{"nctId":"NCT01505179","phase":"NA","title":"The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2011-02","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":10},{"nctId":"NCT01697579","phase":"PHASE2","title":"Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-13","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT01149369","phase":"PHASE2","title":"Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2013-04","conditions":"Gastroparesis","enrollment":126},{"nctId":"NCT02519842","phase":"PHASE3","title":"Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-14","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":75},{"nctId":"NCT03876938","phase":"PHASE3","title":"Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2019-03-01","conditions":"Antiemetic for Highly Emetogenic Chemotherapy","enrollment":147},{"nctId":"NCT02989467","phase":"PHASE1","title":"Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-01-27","conditions":"Healthy","enrollment":27},{"nctId":"NCT01854177","phase":"NA","title":"Differentiating the Effects of Substance P and Beta-endorphin","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2013-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":10},{"nctId":"NCT01362530","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-13","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":307},{"nctId":"NCT01732458","phase":"PHASE2","title":"A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-12","conditions":"Post-operative Nausea, Post-operative Vomiting","enrollment":229},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT00781768","phase":"PHASE4","title":"Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea","status":"COMPLETED","sponsor":"Loyola University","startDate":"2003-08","conditions":"Nausea, Vomiting","enrollment":181},{"nctId":"NCT01874119","phase":"PHASE2","title":"Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma","status":"TERMINATED","sponsor":"St. Louis University","startDate":"2013-09","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":13},{"nctId":"NCT00999544","phase":"NA","title":"Aprepitant Effects on Oxycodone Response","status":"COMPLETED","sponsor":"Sharon Walsh","startDate":"2009-10","conditions":"Narcotic Abuse","enrollment":9},{"nctId":"NCT02210195","phase":"PHASE2","title":"Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"2014-09-04","conditions":"Cannabis Dependence, Alcohol Dependence, Cannabis Use Disorder","enrollment":20},{"nctId":"NCT00952341","phase":"PHASE3","title":"Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-08-25","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":421},{"nctId":"NCT00337727","phase":"PHASE3","title":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-01","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":848},{"nctId":"NCT01625455","phase":"PHASE4","title":"Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2012-02","conditions":"Sezary Syndrome, Pruritus","enrollment":7},{"nctId":"NCT00900068","phase":"","title":"Blood Samples From Patients on a Clinical Trial to CINV During HSCT","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2008-08","conditions":"Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor","enrollment":9},{"nctId":"NCT00248547","phase":"NA","title":"Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2004-05","conditions":"Cancer","enrollment":40},{"nctId":"NCT00034944","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-01-24","conditions":"Major Depressive Disorder","enrollment":495},{"nctId":"NCT00048607","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-07-30","conditions":"Major Depressive Disorder","enrollment":600},{"nctId":"NCT00035048","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-11-21","conditions":"Major Depressive Disorder","enrollment":540},{"nctId":"NCT00042029","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06-18","conditions":"Major Depressive Disorder","enrollment":324},{"nctId":"NCT00048594","phase":"PHASE3","title":"Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-01-03","conditions":"Major Depressive Disorder","enrollment":800},{"nctId":"NCT01611948","phase":"PHASE2","title":"Treatment for Cannabis Withdrawal and Dependence","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"2011-05","conditions":"Cannabis Dependence","enrollment":70},{"nctId":"NCT00035009","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-09-20","conditions":"Major Depressive Disorder","enrollment":468},{"nctId":"NCT00035295","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-11-08","conditions":"Major Depressive Disorder","enrollment":584},{"nctId":"NCT00428519","phase":"PHASE1","title":"Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2007-01","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01432015","phase":"PHASE4","title":"Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Gynecologic Oncology Associates","startDate":"2011-09","conditions":"Ovarian Cancer, Uterine Cancer","enrollment":20},{"nctId":"NCT02550119","phase":"NA","title":"Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2006-04-19","conditions":"Malignant Digestive System Neoplasm, Nausea and Vomiting","enrollment":19},{"nctId":"NCT01300988","phase":"PHASE1","title":"Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-12","conditions":"HIV Infection","enrollment":18},{"nctId":"NCT01205503","phase":"PHASE2","title":"Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release","status":"COMPLETED","sponsor":"Mara Chambers","startDate":"2010-09","conditions":"Breast Cancer, Non-Hodgkin's Lymphoma","enrollment":32},{"nctId":"NCT00475085","phase":"PHASE3","title":"Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial","status":"COMPLETED","sponsor":"Joseph Roscoe","startDate":"2006-12","conditions":"Nausea","enrollment":1021},{"nctId":"NCT00896038","phase":"PHASE2","title":"The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2009-05","conditions":"Alcoholism, Alcohol Dependence, Posttraumatic Stress Disorder","enrollment":58},{"nctId":"NCT02357693","phase":"PHASE4","title":"Neurokinin Receptor Antagonist Associated to Ondansetron in PONV","status":"COMPLETED","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2015-02","conditions":"Postoperative Nausea and Vomiting","enrollment":90},{"nctId":"NCT00990821","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-01","conditions":"Chemotherapy-Induced Nausea and Vomiting, Postoperative Nausea and Vomiting","enrollment":188},{"nctId":"NCT00736073","phase":"NA","title":"A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-08","conditions":"Pancreatitis","enrollment":73},{"nctId":"NCT02431286","phase":"PHASE4","title":"Palonosetron Associated to Aprepitant in Prophylaxis of PONV","status":"UNKNOWN","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2014-10","conditions":"Postoperative Nausea and Vomiting","enrollment":90},{"nctId":"NCT01074697","phase":"PHASE3","title":"Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2010-04","conditions":"Nausea, Vomiting, Genital Neoplasms, Female","enrollment":246},{"nctId":"NCT02407600","phase":"PHASE2","title":"Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy","status":"UNKNOWN","sponsor":"Ajeet Gajra","startDate":"2015-04","conditions":"Non-small Cell Lung Cancer, Vomiting, Nausea","enrollment":150},{"nctId":"NCT00035282","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-09","conditions":"Major Depressive Disorder","enrollment":450},{"nctId":"NCT01402024","phase":"PHASE3","title":"Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2011-08","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":96},{"nctId":"NCT00080444","phase":"PHASE3","title":"Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-04","conditions":"Vomiting","enrollment":50},{"nctId":"NCT00717054","phase":"NA","title":"Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Drexel University","startDate":"2008-02","conditions":"Nausea, Vomiting","enrollment":115},{"nctId":"NCT00659737","phase":"NA","title":"Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"2008-04","conditions":"Nausea, Vomiting","enrollment":115},{"nctId":"NCT00738621","phase":"PHASE4","title":"Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients","status":"COMPLETED","sponsor":"Scott and White Hospital & Clinic","startDate":"2008-07","conditions":"Postoperative Nausea and Vomiting","enrollment":100},{"nctId":"NCT01474915","phase":"PHASE4","title":"Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting","status":"COMPLETED","sponsor":"Sergio Bergese","startDate":"2007-06","conditions":"Postoperative Nausea and Vomiting (PONV), Nausea","enrollment":122},{"nctId":"NCT01393288","phase":"NA","title":"Developing Individualized Strategies to Prevent Nausea and Vomiting","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2013-11","conditions":"Postoperative Nausea and Vomiting, Genetic Polymorphisms","enrollment":""},{"nctId":"NCT00699894","phase":"NA","title":"Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2008-06","conditions":"Postoperative Nausea and Vomiting","enrollment":""},{"nctId":"NCT01580423","phase":"NA","title":"The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2012-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":16},{"nctId":"NCT01897337","phase":"PHASE4","title":"The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-06","conditions":"Postoperative Nausea and Vomiting","enrollment":125},{"nctId":"NCT00659945","phase":"PHASE4","title":"Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2008-06","conditions":"Postoperative Nausea and Vomiting","enrollment":150},{"nctId":"NCT01101529","phase":"PHASE2","title":"Treatment of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Uppsala University Hospital","startDate":"2010-05","conditions":"Nausea, Vomiting","enrollment":90},{"nctId":"NCT00212602","phase":"PHASE2","title":"ONO-7436 Phase II Study in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2005-08","conditions":"Malignant Tumor","enrollment":420},{"nctId":"NCT01204723","phase":"PHASE1","title":"Medications Development for the Treatment of Cannabis Related Disorders","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2009-08","conditions":"Nicotine Withdrawal, Marijuana Dependence, Cannabis Dependence","enrollment":63},{"nctId":"NCT00888329","phase":"PHASE4","title":"Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2007-07","conditions":"Postoperative Nausea and Vomiting","enrollment":256},{"nctId":"NCT00956215","phase":"NA","title":"Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-05","conditions":"Nausea, Vomiting","enrollment":125},{"nctId":"NCT00977223","phase":"PHASE4","title":"Effects of Substance P Antagonists on Adrenal Secretion","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2009-06","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT01088022","phase":"PHASE3","title":"Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting","status":"UNKNOWN","sponsor":"Azienda Ospedaliera di Perugia","startDate":"2010-04","conditions":"Nausea, Vomiting","enrollment":120},{"nctId":"NCT00571168","phase":"PHASE3","title":"Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2005-07","conditions":"Multiple Myeloma","enrollment":362},{"nctId":"NCT00415103","phase":"PHASE4","title":"AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-11","conditions":"Leukemia, Lymphoma","enrollment":196},{"nctId":"NCT00835965","phase":"NA","title":"Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries","status":"UNKNOWN","sponsor":"Main Line Health","startDate":"2009-02","conditions":"Nausea, Vomiting","enrollment":50},{"nctId":"NCT00726960","phase":"PHASE1","title":"Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2008-01","conditions":"Opioid-Related Disorders, Heroin Dependence, Substance-Related Disorders","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":123,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Comparative arm: Placebo of aprepitant administration"],"phase":"phase_3","status":"active","brandName":"Placebo of aprepitant","genericName":"Placebo of aprepitant","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control arm in a clinical trial and contains no active pharmaceutical ingredient. Used for Control arm in aprepitant phase 3 clinical trial (likely chemotherapy-induced nausea and vomiting prevention).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}